The global solid tumor testing market size was valued at USD 29.68 billion in 2025 and is projected to grow from USD 32.05 billion in 2026 to USD 59.23 billion by 2034, registering a CAGR of 7.98% during the forecast period from 2026 to 2034. North America dominated the solid tumor testing market with a market share of 41.8% in 2025.
In cancer, the accumulation of abnormal tissues can result in the formation of solid tumors. Unlike cystic or liquid tumors, solid tumors do not contain any fluid. Solid tumors can be either benign or malignant, depending on their characteristics. Treating solid tumors can be challenging and requires coordinated efforts from various medical professionals, such as surgeons, radiologists, radiation specialists, oncologists, and others. Consequently, chemotherapy, radiation therapy, and operation are the primary treatment modes for most solid tumors. Solid tumors are heterotypic collections of various cell types, including cancer cells, cancer stem cells, connective-tissue cells, and immune cells. Depending on their location, solid tumors can be classified as benign or malignant. Surgery is the treatment option that is currently considered to be the most effective for solid malignant tumors.
Download a Free Sample To learn more about this report,
Growing Adoption of Comprehensive Genomic Profiling and Liquid Biopsy for Precision Oncology
The solid tumor testing market is witnessing significant growth as healthcare providers increasingly use comprehensive genomic profiling, next-generation sequencing, and liquid biopsy technologies to identify actionable biomarkers in cancer patients. Molecular testing enables clinicians to characterize tumors more precisely and select targeted therapies according to specific genetic alterations. Growing use of companion diagnostics and biomarker-guided treatment is expanding testing across lung, breast, colorectal, prostate, and other solid cancers. Liquid biopsy is also gaining importance because it can detect tumor-derived genetic material through minimally invasive blood samples. Continued advances in sequencing and bioinformatics are strengthening personalized cancer care and contributing to overall solid tumor testing market growth.
Growing Adoption of Precision Oncology and Biomarker-Based Cancer Treatment
The solid tumor testing market is witnessing strong growth as cancer treatment increasingly depends on identifying molecular and genetic characteristics within tumors. Next-generation sequencing, immunohistochemistry, PCR, and companion diagnostics are being used to detect biomarkers such as EGFR, ALK, BRAF, HER2, RET, NTRK, and mismatch repair abnormalities. These results can help clinicians select targeted therapies and immunotherapies for patients with lung, breast, colorectal, prostate, and other solid tumors. The continued expansion of biomarker-directed cancer drugs is therefore increasing demand for comprehensive genomic profiling and validated companion diagnostic tests across oncology care.
High Testing Costs and Limited Availability of High-Quality Tumor Samples
The solid tumor testing market faces restraints from the costs and technical complexity associated with genomic sequencing, specialized laboratory infrastructure, bioinformatics, and interpretation of molecular results. Tissue-based testing can also be affected by insufficient biopsy material, low tumor content, sample degradation, and difficulties obtaining repeat biopsies from patients with advanced disease. Although liquid biopsy provides a less invasive alternative, circulating tumor DNA concentrations can vary considerably depending on cancer type, tumor burden, and disease stage. Negative plasma results may therefore require confirmation using conventional tumor tissue testing, increasing diagnostic complexity and potentially extending the time required for treatment decisions.
Expansion of Liquid Biopsy and Comprehensive Genomic Profiling
The solid tumor testing market offers significant opportunities through the growing adoption of blood-based liquid biopsy and comprehensive genomic profiling. Liquid biopsy can provide molecular information from circulating tumor DNA without requiring an invasive tissue biopsy, making it particularly useful when tumor tissue is difficult to obtain or repeat testing is required. Broader genomic panels can simultaneously evaluate numerous cancer-related alterations and potentially reduce the need for multiple sequential tests. Integration of genomic and epigenomic information, artificial intelligence, and advanced bioinformatics could further improve tumor characterization and support increasingly personalized treatment decisions across different solid cancers.
Complex Interpretation of Genomic Data and Standardization of Testing
The solid tumor testing market faces challenges in translating increasingly complex molecular information into clinically actionable treatment decisions. Comprehensive testing can identify numerous genetic alterations, but not every detected variant has an established therapy or clearly understood clinical significance. Laboratories must maintain analytical accuracy while continuously updating interpretation systems as new biomarkers, targeted drugs, and clinical evidence emerge. Differences in sample preparation, sequencing technologies, bioinformatics pipelines, and reporting approaches can further complicate standardization between laboratories. Testing providers must also demonstrate clinical validity and regulatory compliance while delivering results quickly enough to support time-sensitive oncology treatment decisions.
Genetic Testing Dominated the Market with 63.7% Share in 2025
The genetic testing segment accounted for the largest share of the global solid tumor testing market at 63.7% in 2025, driven by increasing use of molecular and genomic technologies to identify cancer-related mutations and biomarkers. Genetic testing supports accurate tumor characterization, treatment selection, and personalized oncology approaches by providing detailed information about the molecular characteristics of solid tumors. Growing adoption of next-generation sequencing, companion diagnostics, biomarker-based therapies, and precision medicine approaches continues to strengthen the use of genetic testing across cancer diagnosis and treatment planning.
Request Customizationto receive a tailored report.
Lung Cancer is Projected to Register the Fastest Growth at a CAGR of 10.72%
The lung cancer segment is projected to register the fastest growth in the solid tumor testing market at a CAGR of 10.72% during the forecast period, supported by increasing use of molecular testing and biomarker analysis for treatment selection. Testing for actionable genetic alterations helps healthcare professionals identify patients who may benefit from targeted therapies and other precision oncology treatments. Growing adoption of comprehensive genomic profiling, liquid biopsy technologies, companion diagnostics, and personalized treatment strategies continues to expand testing requirements for patients with lung cancer.
Pharmaceutical and Biotechnology Companies is Projected to Register the Fastest Growth at a CAGR of 10.84%
The pharmaceutical and biotechnology companies segment is projected to register the fastest growth in the solid tumor testing market at a CAGR of 10.84% during the forecast period, driven by increasing investment in precision oncology, biomarker discovery, targeted therapies, and cancer drug development. These companies use solid tumor testing technologies to support patient stratification, clinical trials, companion diagnostic development, and evaluation of treatment response. Expanding oncology research pipelines and increasing development of biomarker-driven therapies continue to strengthen demand for advanced tumor testing capabilities across pharmaceutical and biotechnology organizations.
Speak to an Analystto discuss market opportunities.
North America dominated the solid tumor testing market with the largest 41.8% market share in 2025, representing a market value of USD 12.41 billion. The region is projected to grow at a CAGR of 8.74% during the forecast period. Its leadership is supported by advanced cancer diagnostic infrastructure, extensive molecular testing capabilities, strong biotechnology and pharmaceutical industries, and increasing adoption of precision oncology. Healthcare providers increasingly use biopsy analysis, molecular diagnostics, next-generation sequencing, immunohistochemistry, and biomarker testing to characterize tumors and guide treatment decisions. Growing integration of genomic information into oncology care is expanding testing requirements. Continued cancer research and development of targeted therapies strengthen North America’s position in the global solid tumor testing market.
The United States is an important contributor to the solid tumor testing market due to its advanced oncology infrastructure, extensive diagnostic laboratory network, and strong biotechnology and pharmaceutical ecosystem. Healthcare providers increasingly use comprehensive genomic profiling, next-generation sequencing, immunohistochemistry, polymerase chain reaction, and other molecular techniques to identify clinically relevant tumor characteristics. Biomarker testing plays an increasingly important role in determining eligibility for targeted therapies and immunotherapies across multiple solid cancers. Specialized cancer centers and diagnostic laboratories also support development and validation of new testing approaches. Continued investment in precision oncology, companion diagnostics, and molecular research supports development of the country's solid tumor testing market.
Canada contributes to the solid tumor testing market through its established healthcare system, cancer treatment centers, molecular diagnostic capabilities, and expanding adoption of precision medicine. Laboratories use tissue-based and molecular testing approaches to characterize solid tumors and provide information that can support treatment selection. Growing use of genomic sequencing and biomarker analysis is improving understanding of tumor-specific alterations across different cancer types. Academic institutions and specialized oncology centers also contribute to research involving molecular diagnostics and personalized cancer treatment. Increasing integration of advanced diagnostic technologies into oncology pathways and continued development of laboratory capabilities support long-term growth of Canada's solid tumor testing market.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific is the fastest-growing region in the solid tumor testing market and is expected to expand at a CAGR of 11.84% during the forecast period. The region accounted for 21.6% of the global market in 2025, representing a market value of USD 6.41 billion. Growth is supported by expanding cancer diagnostic infrastructure, increasing adoption of molecular testing, development of precision oncology programs, and improving access to advanced laboratory technologies. Healthcare providers are increasingly adopting genomic profiling, biomarker testing, and other specialized diagnostic approaches to support tumor classification and treatment selection. Expanding biotechnology capabilities and oncology research further support strong development of the solid tumor testing market across Asia Pacific.
Japan is an important contributor to the solid tumor testing market through its advanced healthcare infrastructure, sophisticated diagnostic capabilities, and established pharmaceutical and biotechnology industries. Oncology providers increasingly use molecular profiling and biomarker testing to identify tumor characteristics that may influence therapeutic decisions. Next-generation sequencing and other advanced laboratory technologies support analysis of multiple genetic alterations across different solid tumor types. Japan's strong biomedical research environment also encourages development of precision oncology and companion diagnostic approaches. Collaboration among healthcare institutions, diagnostic laboratories, pharmaceutical companies, and research organizations supports continued innovation. Increasing integration of molecular information into cancer care strengthens Japan's contribution to the Asia Pacific solid tumor testing market.
China plays a significant role in the solid tumor testing market due to its large healthcare system, expanding oncology infrastructure, growing biotechnology industry, and increasing availability of molecular diagnostic technologies. Hospitals and diagnostic laboratories are adopting genomic sequencing, biomarker testing, immunohistochemistry, and other techniques to characterize solid tumors and support clinical decision-making. Domestic biotechnology companies are expanding capabilities in sequencing technologies, molecular assays, and companion diagnostics. Growing development of targeted oncology medicines is also increasing the importance of identifying relevant molecular alterations in patients. Continued investment in precision medicine, laboratory infrastructure, and cancer research reinforces China's importance within the Asia Pacific solid tumor testing market.
Europe accounted for 28.4% of the global solid tumor testing market in 2025, reaching a market value of USD 8.43 billion. The region is anticipated to grow at a CAGR of 8.96% during the forecast period. Market development is supported by established cancer care systems, advanced diagnostic laboratories, increasing adoption of precision oncology, and continued pharmaceutical research. Healthcare providers use molecular diagnostics, biomarker testing, genomic profiling, and pathology-based approaches to characterize tumors and support treatment planning. Growing availability of targeted therapies is further increasing requirements for accurate identification of clinically relevant biomarkers. Continued development of advanced cancer diagnostics supports expansion of the solid tumor testing market across Europe.
Germany is an important contributor to the solid tumor testing market in Europe due to its advanced healthcare infrastructure, extensive laboratory capabilities, and strong pharmaceutical and biotechnology sectors. Oncology centers increasingly integrate molecular diagnostics with conventional pathology to obtain more detailed information about tumor characteristics. Genomic sequencing and biomarker testing can help identify alterations relevant to targeted therapies and other personalized treatment strategies. Research institutions and diagnostic companies also contribute to development and evaluation of advanced oncology assays. Growing emphasis on precision medicine is encouraging broader integration of molecular information into cancer treatment pathways. Continued diagnostic innovation strengthens Germany's position within the European solid tumor testing market.
The United Kingdom contributes to the solid tumor testing market through its established cancer care system, genomic research capabilities, diagnostic laboratories, and expanding precision oncology activities. Molecular testing is increasingly used alongside traditional pathology to characterize tumors and identify biomarkers relevant to treatment decisions. Healthcare and research institutions are exploring broader use of genomic sequencing to understand cancer biology and support personalized therapeutic approaches. Pharmaceutical research and clinical trials also create demand for reliable diagnostic and biomarker testing capabilities. Continued development of genomic medicine, companion diagnostics, and advanced laboratory technologies supports the United Kingdom's contribution to the European solid tumor testing market.
Latin America represented 5.1% of the global solid tumor testing market in 2025, with a market value of USD 1.51 billion. The region is expected to register a CAGR of 9.38% during the forecast period. Growth is supported by improving oncology infrastructure, expanding molecular diagnostic capabilities, and increasing availability of advanced cancer treatments. Healthcare providers are gradually incorporating biomarker testing and genomic analysis into diagnostic pathways to improve tumor characterization and support treatment selection. Development of specialized laboratories and cancer centers is improving access to sophisticated diagnostic technologies. Continued healthcare modernization and increasing adoption of precision oncology support expansion of the solid tumor testing market across Latin America.
Brazil is an important contributor to the solid tumor testing market in Latin America due to its large healthcare system, established cancer treatment network, and growing molecular diagnostic capabilities. Oncology laboratories increasingly use biomarker analysis, immunohistochemistry, molecular assays, and genomic technologies to obtain detailed information about solid tumors. Increasing availability of targeted therapies is strengthening the importance of identifying molecular characteristics that can guide treatment decisions. Academic institutions, diagnostic laboratories, and specialized cancer centers also contribute to oncology research and testing development. Continued improvement in laboratory infrastructure and adoption of advanced cancer diagnostics reinforce Brazil's importance within the regional solid tumor testing market.
The Middle East and Africa accounted for 3.1% of the global solid tumor testing market in 2025, representing a market value of USD 0.92 billion. The region is projected to expand at a CAGR of 8.52% during the forecast period. Market development is supported by improving oncology infrastructure, investment in specialized healthcare facilities, and increasing availability of molecular diagnostic technologies. Healthcare providers are gradually adopting biomarker testing and advanced pathology approaches to improve tumor characterization and guide treatment decisions. Expansion of diagnostic laboratory capabilities is further improving access to specialized oncology testing. These developments support long-term growth of the solid tumor testing market across the region.
The UAE contributes to the solid tumor testing market within the Middle East and Africa through its advanced healthcare infrastructure, expanding oncology services, and growing adoption of precision medicine technologies. Specialized hospitals and diagnostic laboratories increasingly use molecular assays, biomarker analysis, genomic technologies, and advanced pathology methods to characterize solid tumors. Growing availability of targeted cancer therapies is increasing the importance of accurate molecular testing for treatment selection. Investment in specialized cancer centers and sophisticated laboratory technologies is further improving diagnostic capabilities. Continued healthcare modernization, adoption of genomic medicine, and development of specialized oncology services strengthen the UAE's role in the regional solid tumor testing market.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Flow Cytometry Market Size, Share, Growth, Analysis, Report, 2034
Gene Synthesis Market Size, Share, Growth, Analysis, Report, 2034
Cell Surface Markers Detection Market Size, Share, Growth, 2034
Single-Use Assemblies Market Size, Share, Growth, Analysis, 2034
Cancer Microbiome Sequencing Market Size, Share, Growth, 2034
Inhaled Biologics Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com